Compare SNES & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNES | CLGN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.2M |
| IPO Year | 2016 | 2015 |
| Metric | SNES | CLGN |
|---|---|---|
| Price | $1.29 | $4.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 47.1K |
| Earning Date | 11-09-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,000.00 | N/A |
| Revenue This Year | $57.09 | N/A |
| Revenue Next Year | $50.16 | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.56 | N/A |
| 52 Week Low | $0.55 | $0.26 |
| 52 Week High | $3.61 | $4.78 |
| Indicator | SNES | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.36 | 58.91 |
| Support Level | $0.59 | $0.34 |
| Resistance Level | $1.81 | $4.62 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 86.14 | 56.89 |
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company has developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Its current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.